IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice.
Mucopolysaccharidosis type II (MPSII), or Hunter syndrome, arises from a deficiency in iduronate 2-sulfatase (IDS), and it is characterized by progressive somatic and neurological involvement. The MPSII mouse model reproduces the features of MPSII patients. Systemic administration of the AAV2/5CMV-hIDS vector in MPSII mouse pups results in the full correction of glycosaminoglycan (GAG) accumulation in visceral organs and in the rescue of the defects and GAG accumulation in the central nervous system (CNS). Remarkably, in treated MPSII animals, this CNS correction arises from the crossing of the blood-brain barrier by the IDS enzyme itself, not from the brain transduction. Thus, we show here that early treatment of MPSII mice with one systemic injection of AAV2/5CMV-hIDS results in prolonged and high levels of circulating IDS that can efficiently and simultaneously rescue both visceral and CNS defects for up to 18 months after therapy.
Polito
Vinicia Assunta
VA
Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Cosma
Maria Pia
MP
D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001921:Brain / Q000166:cytology / Q000378:metabolism; D002490:Central Nervous System / Q000378:metabolism*; D000229:Dependovirus / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D007066:Iduronate Sulfatase / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D007275:Injections, Intravenous; D008099:Liver / Q000166:cytology / Q000378:metabolism; D008168:Lung / Q000166:cytology / Q000378:metabolism; D008247:Lysosomes / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D016532:Mucopolysaccharidosis II / Q000378:metabolism*; D016019:Survival Analysis
D006025:Glycosaminoglycans; D007066:Iduronate Sulfatase
Pharmacol Rev. 2005 Jun;57(2):173-85
15914466
Nat Biotechnol. 2009 Jan;27(1):59-65
19098898
Cell. 2003 May 16;113(4):445-56
12757706
J Virol. 2001 Jul;75(13):6199-203
11390622
Mol Ther. 2004 Sep;10(3):478-91
15336648
J Clin Invest. 2002 Aug;110(4):499-504
12189244
Cell. 2003 May 16;113(4):435-44
12757705
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2616-21
18268347
Acta Paediatr Suppl. 2002;91(439):98-9
12572850
Mol Ther. 2009 Apr;17(4):600-6
19174759
Hum Mutat. 1993;2(6):435-42
8111411
Acta Neuropathol. 2007 Nov;114(5):481-9
17653558
Hum Mol Genet. 2004 Sep 15;13(18):1979-88
15269179
Hum Mol Genet. 2006 Apr 1;15(7):1225-36
16505002
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14777-82
16162667